TN2018000212A1 - Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof - Google Patents
Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereofInfo
- Publication number
- TN2018000212A1 TN2018000212A1 TNP/2018/000212A TN2018000212A TN2018000212A1 TN 2018000212 A1 TN2018000212 A1 TN 2018000212A1 TN 2018000212 A TN2018000212 A TN 2018000212A TN 2018000212 A1 TN2018000212 A1 TN 2018000212A1
- Authority
- TN
- Tunisia
- Prior art keywords
- binding proteins
- antigen binding
- tnf
- bispecific antigen
- antigen
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title abstract 6
- 108091000831 antigen binding proteins Proteins 0.000 title abstract 6
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention concerns antigen binding proteins that bind TLlA, including bispecific antigen binding proteins (e.g., antibodies) to TUA and TNF-a. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TUA and the other to TNF-a. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other.The bispecific antigen binding protein may also be comprised in an lgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TLlA binding proteins and anti-TL 1 A/ anti-TNF-a antigen binding proteins, and pharmaceutical formulations thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268432P | 2015-12-16 | 2015-12-16 | |
| PCT/US2016/052006 WO2017049004A1 (en) | 2015-09-15 | 2016-09-15 | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof |
| PCT/US2016/066722 WO2017106383A1 (en) | 2015-12-16 | 2016-12-14 | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2018000212A1 true TN2018000212A1 (en) | 2019-10-04 |
Family
ID=61768598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2018/000212A TN2018000212A1 (en) | 2015-12-16 | 2016-12-14 | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR107075A1 (en) |
| TN (1) | TN2018000212A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020323542A1 (en) * | 2019-08-01 | 2022-03-17 | Memorial Hospital For Cancer And Allied Diseases | Cells for improved immunotherapy and uses thereof |
-
2016
- 2016-12-14 TN TNP/2018/000212A patent/TN2018000212A1/en unknown
- 2016-12-16 AR ARP160103884A patent/AR107075A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR107075A1 (en) | 2018-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501284A1 (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
| PH12021500051A1 (en) | Cd3 antigen binding fragments and compositions comprising same | |
| CR20170383A (en) | ANTI-CD3 ANTIBODIES, ANTI-CD-123 ANTIBODIES AND BIESPECIFIC ANTIBODIES THAT SPECIFICALLY JOIN CD3 AND / OR CD123 | |
| MX2023007520A (en) | IMPROVED WHEY ALBUMIN BINDERS. | |
| WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
| EA201391159A1 (en) | HLA-Restricted Peptidospecific Antigen Binding Proteins | |
| CL2011003148A1 (en) | Bispecific antigen-binding protein, comprising a) 2 light chains and 2 heavy chains of an antibody that specifically binds to one antigen and 2 fab fragments, b) two additional fab fragments of an antibody that specifically bind to a second antigen ; Preparation method; pharmaceutical composition and use. | |
| WO2013136186A3 (en) | Readily isolated bispecific antibodies with native immunoglobulin format | |
| EA201491599A1 (en) | ANTIBODIES TO MATRIX METALLOPROTEINASE 9 | |
| EA201200526A1 (en) | POLYVALENT ANTIBODIES STABILIZED BY DISULFIDE | |
| MX2013011176A (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation. | |
| EA201491575A1 (en) | ANTIBODIES TO MATRIX METALLOPROTEINASE 9 | |
| WO2015006337A3 (en) | Compositions and methods for increasing protein half-life in a serum | |
| JOP20200215A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| MX2022009915A (en) | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof. | |
| MX2018005831A (en) | Opposite ph-salt gradients for improved protein separations. | |
| BR112014019773A8 (en) | BINDERS FOR ANTIBODY AND FC FUSION PROTEIN FOR AFFINITY CHROMATOGRAPHY | |
| EP4495142A3 (en) | Bispecific antigen binding construct | |
| TN2018000212A1 (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
| MX2019003908A (en) | Multi-protease method. | |
| MX2021012178A (en) | Engineering of an antibody for tumor-selective binding of cd47. | |
| WO2011130644A3 (en) | Phosphorylated nf45 biomarkers, antibodies and methods of using same | |
| EA202090581A1 (en) | FUSION PRODUCTS OF TRANSTYRETIN AND IMMUNOGLOBULIN | |
| MX2019002455A (en) | Methods of identifying epitopes. | |
| ECSP21028958A (en) | MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO CD20 ANTIGEN |